Synairgen’s time riding the COVID-19 wave has come crashing to a close. Its inhaled interferon beta candidate SNG001 posted a clean sweep of failures against key endpoints in a phase 3 clinical trial of hospitalized COVID-19 patients, prompting investors to flee despite Synairgen’s search for a silver lining. Source: Fierce Biotech 22/02/2022